
SCTX Stock Forecast & Price Target
SCTX Analyst Ratings
Bulls say
Scribe Therapeutics is viewed positively because STX-1150 has already shown a compelling preclinical profile, with >50% LDL-C lowering sustained for two years in NHPs, no significant liver-safety signal, and >5x higher potency in human hepatocytes than in cynomolgus cells, suggesting a credible path to low-dose human activity. Its ELXR platform could fill a differentiated niche between chronic PCSK9 drugs and permanent genome editing by preserving DNA sequence while offering the convenience of one infusion and the potential for years of LDL-C control, which directly addresses poor adherence in a market where current PCSK9 therapies still generate about $5.1 billion in annual global sales. Financially, the company appears undervalued relative to strategic precedent, with an estimated enterprise value of about $360 million versus Verve’s $549 million net-cash takeout, while pro forma cash and no debt support runway into 1H29 and funding for the 1H27 readout and initial XE development.
Bears say
Scribe Therapeutics is viewed skeptically because its value depends on first-in-human proof that STX-1150 can translate preclinical promise into durable, safe human efficacy, yet ELXR/XE have no clinical data and the company expects no product revenue in 2026 or 2027. Its balance sheet is not strong enough to eliminate risk, with about $170 million of cash and management guidance only into 1H29, while continued losses, potential dilution, and collaboration revenue of just $11.5 million in FY2026 and $6.7 million in FY2027 underscore the lack of near-term commercialization. Competitive and reimbursement pressures are also severe, as established and advancing PCSK9 and Lp(a) therapies may reach the market first, and Scribe’s one-time IV genetic medicines must prove they can win on efficacy, safety, cost, and adoption.
This aggregate rating is based on analysts' research of Scribe Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
SCTX Analyst Forecast & Price Prediction
Start investing in SCTX
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Scribe Therapeutics Inc (SCTX) Forecast
SCTX Analyst Forecast & Price Prediction
Start investing in SCTX
Order type
Buy in
Order amount
Est. shares
0 shares